SWOG clinical trial number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Open
Abbreviated Title
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer
Activated
05/06/2024

Research committees

Gastrointestinal Cancer

Treatment

Ramucirumab Nivolumab Paclitaxel